Роль лактоферрина и тиндаллизированных лактобактерий в эрадикации условно-патогенных микроорганизмов и восстановлении эубиоза влагалища

1. Muzny C.A., Łaniewski P., Schwebke J.R., Herbst-Kralovetz M.M. Host-vaginal microbiota interactions in the pathogenesis of bacterial vaginosis. Curr. Opin. Infect. Dis. 2020; 33(1): 59-65. https://dx.doi.org/10.1097/QCO.0000000000000620
2. Ma X., Wu M., Wang C., Li H., Fan A., Wang Y. et al. The pathogenesis of prevalent aerobic bacteria in aerobic vaginitis and adverse pregnancy outcomes: a narrative review. Reprod. Health. 2022; 19(1): 21. https://dx.doi.org/10.1186/s12978-021-01292-8
3. Jahic M. Aerobic vaginitis caused by Enterococcus Faecalis – clinical features and treatment. Mater. Sociomed. 2022; 34(4): 291-5. https://dx.doi.org/10.5455/msm.2022.34.291-295
4. Blostein F., Levin-Sparenberg E., Wagner J., Foxman B. Recurrent vulvovaginal candidiasis. Ann. Epidemiol. 2017; 27(9): 575-82e. https://dx.doi.org/10.1016/j.ajog.2015.06.067
5. Foxman B., Muraglia R., Dietz J.P., Sobel J.D., Wagner J. Prevalence of recurrent vulvovaginal candidiasis in 5 European countries and the United States: results from an internet panel survey. J. Low. Genit. Tract Dis. 2013; 17(3): 340-5. https://dx.doi.org/10.1097/LGT.0b013e318273e8cf
6. Kalia N., Singh J., Kaur M. Microbiota in vaginal health and pathogenesis of recurrent vulvovaginal infections: a critical review. Ann. Clin. Microbiol. Antimicrob. 2020; 19(1): 5. https://dx.doi.org/10.1186/s12941-020-0347-4
7. Пунченко О.Е., Березницкая Е.А., Ермоленко Е.И. Микробиота женских половых органов: норма, патология, пути коррекции. Акушерство и гинекология. 2021; 3: 18-24.
8. Belayneh M., Sehn E., Korownyk C. Recurrent vulvovaginal candidiasis. Can. Fam. Physician. 2017; 63(6): 455.
9. Yang S., Zhang Y., Liu Y., Wang J., Chen S., Li S. Clinical significance and characteristic clinical differences of cytolytic vaginosis in recurrent vulvovaginitis. Gynecol. Obstet. Invest. 2017; 82(2): 137-43. https://dx.doi.org/10.1159/000446945
10. Sobel J.D., Kaur N., Woznicki N.A., Boikov D., Aguin T., Gill G. et al. Prognostic indicators of recurrence of bacterial vaginosis. J. Clin. Microbiol. 2019; 57(5): e00227-19. https://dx.doi.org/10.1128/JCM.00227-19
11. Mollin A., Katta M., Sobel J.D., Akins R.A. Association of key species of vaginal bacteria of recurrent bacterial vaginosis patients before and after oral metronidazole therapy with short- and long-term clinical outcomes. PLOS One. 2022; 17(7): e0272012. https://dx.doi.org/10.1371/journal.pone.0272012
12. Turner E., Sobel J.D., Akins R.A. Prognosis of recurrent bacterial vaginosis based on longitudinal changes in abundance of Lactobacillus and specific species of Gardnerella. PLOS One. 2021; 16(8): e0256445. https://dx.doi.org/10.1371/journal.pone.0256445
13. Uddin T.M., Chakraborty A.J., Khusro A., Zidan B.R.M., Mitra S., Emran T.B. et al. Antibiotic resistance in microbes: history, mechanisms, therapeutic strategies and future prospects. J. Infect. Public. Health. 2021; 14(12): 1750-66. https://dx.doi.org/10.1016/j.jiph.2021.10.020
14. Hashemi S.E., Shokohi T., Abastabar M., Aslani N., Ghadamzadeh M., Haghani I. Species distribution and susceptibility profiles of Candida species isolated from vulvovaginal candidiasis, emergence of C. lusitaniae. Curr. Med. Mycol. 2019; 5(4): 26-34. https://dx.doi.org/10.18502/cmm.5.4.2062
15. O’Neill J. Tackling drug-resistant infections globally: final report and recommendations. The review on antimicrobial resistance. London, UK: HM Government and the Wellcome Trust.
16. Abavisani M., Sahebi S., Dadgar F., Peikfalak F., Keikha M. The role of probiotics as adjunct treatment in the prevention and management of gynecological infections: an updated meta-analysis of 35 RCT studies. Taiwan. J. Obstet. Gynecol. 2024; 63(3): 357-68. https://dx.doi.org/10.1016/j.tjog.2024.03.004
17. Malfa P., Brambilla L., Giardina S., Masciarelli M., Squarzanti D.F., Carlomagno F. et al. Evaluation of antimicrobial, antiadhesive and co-aggregation activity of a multi-strain probiotic composition against different urogenital pathogens. Int. J. Mol. Sci. 2023; 24(2): 1323. https://dx.doi.org/10.3390/ijms24021323
18. Swidsinski A., Guschin A., Tang Q., Dörffel Y., Verstraelen H., Tertychnyy A. et al. Vulvovaginal candidiasis: histologic lesions are primarily polymicrobial and invasive and do not contain biofilms. Am. J. Obstet. Gynecol 2019; 220: 91.e1-8. https://dx.doi.org/10.1016/j.ajog.2018.10.023
19. McKloud E., Delaney C., Sherry L., Kean R., Williams S., Metcalfe R. et al. Recurrent vulvovaginal candidiasis: a dynamic interkingdom biofilm disease of Candida and Lactobacillus. mSystems. 2021; 6(4): e0062221. https://dx.doi.org/10.1128/mSystems.00622-21
20. Parolin C., Croatti V., Giordani B., Vitali B. Vaginal Lactobacillus impair Candida dimorphic switching and biofilm formation. Microorganisms. 2022; 10(10): 2091. https://dx.doi.org/10.3390/microorganisms10102091
21. Amabebe E., Anumba D.O.C. The vaginal microenvironment: the physiologic role of Lactobacilli. Front. Med. (Lausanne). 2018; 5: 181. https://dx.doi.org/10.3389/fmed.2018.00181
22. Van de Wijgert J., Verwijs M.C. Lactobacilli-containing vaginal probiotics to cure or prevent bacterial or fungal vaginal dysbiosis: a systematic review and recommendations for future trial designs. BJOG. 2020; 127(2): 287-99. https://dx.doi.org/10.1111/1471-0528.15870
23. Gonciarz R.L., Renslo A.R. Emerging role of ferrous iron in bacterial growth and host-pathogen interaction: new tools for chemical (micro)biology and antibacterial therapy. Curr. Opin. Chem. Biol. 2021; 61: 170-8. https://dx.doi.org/10.1016/j.cbpa.2021.01.015
24. Chandrangsu P., Rensing C., Helmann J.D. Metal homeostasis and resistance in bacteria. Nat. Rev. Microbiol. 2017; 15(6): 338-50. https://dx.doi.org/10.1038/nrmicro.2017.15
25. Moreira A.C., Silva T., Mesquita G., Gomes A.C., Bento C.M., Neves J.V. et al. H-ferritin produced by myeloid cells is released to the circulation and plays a major role in liver iron distribution during infection. Int. J. Mol. Sci. 2021; 23(1): 269. https://dx.doi.org/10.3390/ijms23010269
26. Porcheron G., Dozois C.M. Interplay between iron homeostasis and virulence: Fur and RyhB as major regulators of bacterial pathogenicity. Vet. Microbiol. 2015; 179(1-2): 2-14. https://dx.doi.org/10.1016/j.vetmic.2015.03.024
27. Artym J., Zimecki M. Antimicrobial and prebiotic activity of lactoferrin in the female reproductive tract: a comprehensive review. Biomedicines. 2021; 9(12): 1940. https://dx.doi.org/10.3390/biomedicines9121940
28. Valenti P., Rosa L., Capobianco D., Lepanto M.S., Schiavi E., Cutone A. et al. Role of Lactobacilli and Lactoferrin in the mucosal cervicovaginal defense. Front. Immunol. 2018; 9: 376. https://dx.doi.org/10.3389/fimmu.2018.00376
29. Pino A., Mazza T., Matthews M.H., Castellana S., Caggia C., Randazzo C.L. et al. Antimicrobial activity of bovine lactoferrin against Gardnerella species clinical isolates. Front. Microbiol. 2022; 13: 1000822. https://dx.doi.org/10.3389/fmicb.2022.1000822
30. Pino A., Giunta G., Randazzo C., Caruso S., Caggia C., Cianci A. Bacterial biota of women with bacterial vaginosis treated with lactoferrin: an open prospective randomized trial. Microb. Ecol. Health Dis. 2017; 28(1): 1357417. https://dx.doi.org/10.1080/16512235.2017.1357417
31. Sessa R., Di Pietro M., Filardo S., Bressan A., Rosa L., Cutone A. et al. Effect of bovine lactoferrin on Chlamydia trachomatis infection and inflammation. Biochem. Cell. Biol. 2017; 95(1): 34-40. https://dx.doi.org/10.1139/bcb-2016-0049
32. Liao H., Liu S., Wang H., Su H., Liu Z. Enhanced antifungal activity of bovine lactoferrin-producing probiotic Lactobacillus casei in the murine model of vulvovaginal candidiasis. BMC Microbiol. 2019; 19(1): 7. https://dx.doi.org/10.1186/s12866-018-1370-x
33. Russo R., Superti F., Karadja E., De Seta F. Randomised clinical trial in women with recurrent vulvovaginal Candidiasis: efficacy of probiotics and lactoferrin as maintenance treatment. Mycoses. 2019; 62(4): 328-35. https://dx.doi.org/10.1111/myc.12883
34. Rosa L., Cutone A., Conte M.P., Campione E., Bianchi L., Valenti P. An overview on in vitro and in vivo antiviral activity of lactoferrin: its efficacy against SARS-CoV-2 infection. Biometals. 2023; 36(3): 417-36. https://dx.doi.org/10.1007/s10534-022-00427-z
35. Kaplan M., Baktıroğlu M., Kalkan A.E., Canbolat A.A., Lombardo M., Raposo A. et al. Lactoferrin: a promising therapeutic molecule against Human Papillomavirus. Nutrients. 2024; 16(18): 3073. https://dx.doi.org/10.3390/nu16183073
36. Gibson G.R., Hutkins R., Sanders M.E., Prescott S.L., Reimer R.A., Salminen S.J. et al. Expert consensus document: the International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat. Rev. Gastroenterol. Hepatol. 2017; 14(8): 491-502. https://dx.doi.org/10.1038/nrgastro.2017.75
37. Liu Z.S., Lin C.F., Chen P.W. Transcriptome analysis of Lactobacillus rhamnosus GG strain treated with prebiotic – bovine lactoferrin under a cold environment. J. Food Drug Anal. 2021; 29(3): 402-18. https://dx.doi.org/10.38212/2224-6614.3369
38. Chen P.W., Liu Z.S., Kuo T.C., Hsieh M.C., Li Z.W. Prebiotic effects of bovine lactoferrin on specific probiotic bacteria. Biometals. 2017; 30(2): 237-48. https://dx.doi.org/10.1007/s10534-017-9999-8
39. Vega-Bautista A., de la Garza M., Carrero J.C., Campos-Rodríguez R., Godínez-Victoria M., Drago-Serrano M.E. The impact of lactoferrin on the growth of intestinal inhabitant bacteria. Int. J. Mol. Sci. 2019; 20(19): 4707. https://dx.doi.org/10.3390/ijms20194707
40. Nader-Macías M.E.F., De Gregorio P.R., Silva J.A. Probiotic lactobacilli in formulas and hygiene products for the health of the urogenital tract. Pharmacol. Res. Perspect. 2021; 9(5): e00787. https://dx.doi.org/10.1002/prp2.787
41. Russo R., Edu A., De Seta F. Study on the effects of an oral lactobacilli and lactoferrin complex in women with intermediate vaginal microbiota. Arch. Gynecol. Obstet. 2018; 298(1): 139-45. https://dx.doi.org/10.1007/s00404-018-4771-z
42. Trentini A., Maritati M., Rosta V., Cervellati C., Manfrinato M.C., Hanau S. et al. Vaginal lactoferrin administration decreases oxidative stress in the amniotic fluid of pregnant women: an open-label randomized pilot study. Front. Med. (Lausanne). 2020; 7: 555. https://dx.doi.org/10.3389/fmed.2020.00555
43. Ali A.E., Fathi M.A., Mohammed A.I. Efficacy of lactoferrin in prevention of premature rupture of membrane. Egypt. J. Hosp. Med. 2021; 85: 2823-7. https://dx.doi.org/10.21608/ejhm.2021.190182
44. Eker F., Duman H., Ertürk M., Karav S. The potential of lactoferrin as antiviral and immune-modulating agent in viral infectious diseases. Front. Immunol. 2024; 15: 1402135. https://dx.doi.org/10.3389/fimmu.2024.1402135
45. Superti F., De Seta F. Warding off recurrent yeast and bacterial vaginal Infections: lactoferrin and lactobacilli. Microorganisms. 2020; 8(1): 130. https://dx.doi.org/10.3390/microorganisms8010130
46. Wang Z., He Y., Zheng Y. Probiotics for the treatment of bacterial vaginosis: a meta-analysis. Int. J. Environ. Res. Public Health. 2019; 16(20): 3859. https://dx.doi.org/10.3390/ijerph16203859
47. Pytka M., Kordowska-Wiater M., Jarocki P. Microbiome of the women’s genital tract. Adv. Microbiol. 2019; 58: 227-36. https://dx.doi.org/10.21307/PM-2019.58.3.227
48. Кира Е.Ф., Припутневич Т.В., Кира Е.Е. Биологические и биохимические защитные факторы влагалища и цервикального канала: механизмы стабильности и варианты коррекции. Акушерство и гинекология. 2025; 3: 30-42.
49. Piqué N., Berlanga M., Miñana-Galbis D. Health benefits of heat-killed (Tyndallized) probiotics: an overview. Int. J. Mol. Sci. 2019; 20(10): 2534. https://dx.doi.org/10.3390/ijms20102534
50. De Marco S., Sichetti M., Muradyan D., Piccioni M., Traina G., Pagiotti R. et al. Probiotic cell-free supernatants exhibited anti-inflammatory and antioxidant activity on human gut epithelial cells and macrophages stimulated with LPS. Evid. Based Complement. Alternat. Med. 2018; 2: 1-12. https://dx.doi.org/10.1155/2018/1756308
51. Elughi G.N., Oniha M.I., Obafemi Y.D., Akinyosoye A.D., Ahuekwe E.F., Akinduti P.A. Antibacterial activity of cell-free supernatants of probiotic lactobacillus against bacterial pathogens associated with vaginal infections. J. Pure Appl. Microbiol. 2024; 18(1): 451-9. https://dx.doi.org/10.22207/JPAM.18.1.28
52. Moon E.C., Park M.S., Lim T., Kim R.H., Ji G.E., Kim S.Y. et al. Antibacterial effect of cell-free supernatant fraction from Lactobacillus paracasei CH88 against Gardnerella vaginalis. Sci. Rep. 2022; 12(1): 4763. https://dx.doi.org/10.1038/s41598-022-08808-7
53. Scillato M., Spitale A., Mongelli G., Privitera G.F., Mangano K., Cianci A. et al. Antimicrobial properties of Lactobacillus cell-free supernatants against multidrug-resistant urogenital pathogens. Microbiologyopen. 2021; 10(2): e1173. https://dx.doi.org/10.1002/mbo3.1173
54. Barea B.M., Veeratterapillay R., Harding C. Nonantibiotic treatments for urinary cystitis: an update. Curr. Opin. Urol. 2020; 30(6): 845-52. https://dx.doi.org/10.1097/MOU.0000000000000821
55. Drumond M.M., Tapia-Costa A.P., Neumann E., Nunes Á.C., Barbosa J.W., Kassuha D.E. et al. Cell-free supernatant of probiotic bacteria exerted antibiofilm and antibacterial activities against Pseudomonas aeruginosa: a novel biotic therapy. Front. Pharmacol. 2023; 14: 1152588. https://dx.doi.org/10.3389/fphar.2023.1152588
56. Zanetta P., Ballacchino C., Squarzanti D.F., Amoruso A., Pane M., Azzimonti B. Lactobacillus johnsonii LJO02 (DSM 33828) cell-free supernatant and vitamin D improve wound healing and reduce interleukin-6 production in Staphylococcus aureus infected human keratinocytes. Pharmaceutics. 2023; 16(1): 18. https://dx.doi.org/10.3390/pharmaceutics16010018
57. Gökalp F. An investigation of the olive phenols activity as a natural medicine. J. Food Drug Anal. 2018; 26(2): 657-61. https://dx.doi.org/10.1016/j.jfda.2017.07.003
58. Di Pietro M., Filardo S., Mattioli R., Francioso A., Raponi G., Mosca L. et al. Extra virgin olive oil-based green formulations with promising antimicrobial activity against drug-resistant isolates. Front. Pharmacol. 2022; 13: 885735. https://dx.doi.org/10.3389/fphar.2022.885735
59. Bucciantini M., Leri M., Nardiello P., Casamenti F., Stefani M. Olive polyphenols: antioxidant and anti-inflammatory properties. Antioxidants (Basel). 2021; 10(7): 1044. https://dx.doi.org/10.3390/antiox10071044
60. Lin T.K., Zhong L., Santiago J.L. Anti-inflammatory and skin barrier repair effects of topical application of some plant oils. Int. J. Mol. Sci. 2017; 19(1): 70. https://dx.doi.org/10.3390/ijms19010070
61. González-Acedo A., Ramos-Torrecillas J., Illescas-Montes R., Costela-Ruiz V.J., Ruiz C., Melguizo-Rodríguez L. et al. The benefits of olive oil for skin health: study on the effect of hydroxytyrosol, tyrosol, and oleocanthal on human fibroblasts. Nutrients. 2023; 15(9): 2077. https://dx.doi.org/10.3390/nu15092077
62. Sánchez-Quesada C., López-Biedma A., Toledo E., Gaforio J.J. Squalene stimulates a key innate immune cell to foster wound healing and tissue repair. Evid. Based Complement. Alternat. Med. 2018; 2018: 9473094. https://dx.doi.org/10.1155/2018/9473094
63. Melguizo-Rodríguez L., de Luna-Bertos E., Ramos-Torrecillas J., Illescas-Montesa R., Costela-Ruiz V.J., García-Martínez O. Potential effects of phenolic compounds that can be found in olive oil on wound healing. Foods. 2021; 10(7): 1642. https://dx.doi.org/10.3390/foods10071642
64. Taheri M., Amiri-Farahani L. Anti-inflammatory and restorative effects of olives in topical application. Dermatol. Res. Pract. 2021; 2021: 9927976. https://dx.doi.org/10.1155/2021/9927976
65. Harwood A., Nassereddin A., Krishnamurthy K. Moisturizers. 2024 Feb 12. In: StatPearls
66. Miranda M., Saccone G., Ammendola A., Salzano E., Iannicelli M., De Rosa R. et al. Vaginal lactoferrin in prevention of preterm birth in women with bacterial vaginosis. J Matern. Fetal Neonatal. Med. 2021; 34(22): 3704-8. https://dx.doi.org/10.1080/14767058.2019.1690445
67. D'Amico A., Buca D., Tinari S., Oronzii L., Lucidi A., Di Sebastiano F. et al. Role of lactoferrin in preventing preterm birth and pregnancy complications: a systematic review and meta-analysis. Minerva Obstet. Gynecol. 2023; 75(3): 273-8. https://dx.doi.org/10.23736/S2724-606X.22.05032-1
68. Juraskova I., Jarvis S., Mok K., Peate M., Meiser B., Cheah B.C. et al. The acceptability, feasibility, and efficacy (phase I/II study) of the OVERcome (Olive Oil, Vaginal Exercise, and MoisturizeR) intervention to improve dyspareunia and alleviate sexual problems in women with breast cancer. J. Sex. Med. 2013; 10(10): 2549-58. https://dx.doi.org/10.1111/jsm.12156
69. Vale F., Rezende C., Raciclan A., Bretas T., Geber S. Efficacy and safety of a non-hormonal intravaginal moisturizer for the treatment of vaginal dryness in postmenopausal women with sexual dysfunction. Eur. J. Obstet. Gynecol. Reprod. Biol. 2019; 234: 92-5. https://dx.doi.org/10.1016/j.ejogrb.2018.12.040
70. Archer D.F., Goldstein S.R., Simon J.A., Waldbaum A.S., Sussman S.A., Altomare C. et al. Efficacy and safety of ospemifene in postmenopausal women with moderate-to-severe vaginal dryness: a phase 3, randomized, double-blind, placebo-controlled, multicenter trial. Menopause. 2019; 26(6): 611-21. https://dx.doi.org/10.1097/GME.0000000000001292
71. Sacarin G., Abu-Awwad A., Razvan N., Craina M., Hogea B., Sorop B. et al. Sexual quality of life in postmenopausal women: a comparative randomized controlled trial of intravaginal PRP therapy versus local hormonal treatments. Medicina (Kaunas). 2025; 61(7): 1140. https://dx.doi.org/10.3390/medicina61071140

Поступила 15.08.2025

Принята в печать 21.08.2025